Halma bets €275M on pathology lab automation with Dreampath deal
What's the deal? HalmaDealroom has a profile for this one. Try Dealroom →, the FTSE 100 group known for life-saving technology, is acquiring French pathology tech firm Dreampath DiagnosticsDealroom has a profile for this one. Try Dealroom → for up to €275m. The Strasbourg-based company automates the storage, tracking, and management of patient tissue samples in anatomical pathology labs.
The numbers: Halma will pay an initial €154m (about £132m) in cash on a cash- and debt-free basis, funded through existing credit facilities. A further earn-out of up to €121m (roughly £104m) is tied to performance over two years ending March 31, 2027 and 2028, split 38% and 62% respectively.
Dreampath is forecast to generate €33m (about £28m) in revenue for the 12 months to March 31, 2027. Its closed-loop system combines hardware, software, and consumables, with a high proportion of recurring revenue.
Why now? International regulations now require tissue samples to be retained for at least 10 years, pressuring labs to find secure, traceable, and scalable storage. Dreampath automates what has traditionally been a manual process, cutting the risk of mislabelled or lost samples.
What's the endgame? The deal slots into Halma's Healthcare Sector, adding capabilities in tissue sample traceability, archiving, and lifecycle management. Dreampath will operate as a standalone business, keeping its current management team.
Group chief executive Marc Ronchetti framed the deal as a bet on long-term trends: "Dreampath is a high-quality business in a growing area of diagnostics." Dreampath chief executive Pablo JordanDealroom has a profile for this one. Try Dealroom → said Halma offered "that combination of autonomy, ambition and support."
The signal: The €275m price tag marks a step up for Halma, which also in July 2026 announced two smaller healthcare bolt-ons — Dutch itemedicalDealroom has a profile for this one. Try Dealroom → and Swedish Naslund Medical ABDealroom has a profile for this one. Try Dealroom → — for a combined £54m. Dreampath, which took growth investment from Summit Partners in mid-2025, signals intensifying consolidation in lab automation and digital pathology, with financial sponsors exiting into strategic buyers chasing higher-margin, software-enabled healthcare technology.
Read more: newsnreleases.com
Image credit: USDAgov
